De novo extended-release Tacrolimus in Kidney Transplant Patients; Is it safe?

Authors : Mahmud İSLAM, Necattin FIRAT, Musa PINAR, Kenan Evren ÖZTOP, Gözde ÇAKIRSOY ÇAKAR, Zafer ERCAN, Enes SARIGEDİK, Hamad DHEİR

Pages : 478-483

Doi:10.31832/smj.1326320

View : 27 | Download : 41

Publication Date : 2023-09-30

Article Type : Research Paper

Abstract :Background: This study aimed to investigate whether de novo extended-release tacrolimus insert ignore into journalissuearticles values(ERT); therapy is safe in kidney recipients. Methods: The study was single-center, retrospective, and included a total of 57 patients, including 30 patients in the ERT group insert ignore into journalissuearticles values(Group 1); and 27 patients in the immediate-release tacrolimus insert ignore into journalissuearticles values(IRT); group insert ignore into journalissuearticles values(Group 2);. Demographic and laboratory characteristics of the patients were recorded. Complications such as acute drug toxicity, acute rejection, new-onset diabetes mellitus after transplantation, and development of hypertension, opportunistic infection, and hospitalization data were recorded. Results: The mean age of the patients was 46.23±14.2 years in the ERT group and 47.04±14.6 years in the IRT group. There were 21 insert ignore into journalissuearticles values(70%); males in group 1, while 20 insert ignore into journalissuearticles values(74%); patients in group 2 had a male gender insert ignore into journalissuearticles values(P=0.73);. The rate of improved serum creatinine values in the first week postoperatively was similar in both groups. While the mean tacrolimus levels on postoperative day 1 were significantly lower in the group- 1 insert ignore into journalissuearticles values(P<0.05);, there was no significant difference between tacrolimus levels on postoperative days 2-7. There was no significant difference between the groups regarding opportunistic infections, diabetes mellitus, and the need for hospitalization in the first six months of follow-up. Conclusion: Initiation of de novo extended-release tacrolimus therapy in kidney recipients is safe in the long term and preserves graft function.
Keywords : Böbrek nakli, uzatılmış salımlı takrolimus, hızlı salımlı takrolimus, greft fonksiyonu